Michele Ilene Korfin

Michele Ilene Korfin

Chief Operating and Chief Commercial Officer at Gamida Cell Ltd.

Are you Michele Ilene Korfin? Claim your profile
 
  • IDENTIFY executive and board member connections in Michele Ilene Korfin's network.
  • FOLLOW changes in Michele Ilene Korfin's employment.
  • CONNECT with Michele Ilene Korfin through your network of contacts.

Michele Ilene Korfin's Executive Work History


Current
Chief Operating and Chief Commercial Officer,
Chief Operating and Chief Commercial Officer
Gamida Cell Ltd. DEF 14A on 06/22/2022
Gamida Cell Ltd.
Board Member,
Board Member
Organogenesis Holdings Inc. DEF 14A on 05/10/2022
Organogenesis Holdings Inc.
Secretary,
Secretary
Equilar on 01/18/2023
BioNJ
Board Member,
Board Member
Equilar on 02/09/2022
BioNJ
Past
To view Michele Ilene Korfin's complete executive work history,
Age
50
 

Michele Ilene Korfin's Biography


Michele Korfin has over 25 years of experience in the biotech/pharma industry, focused on product launches, clinical development, manufacturing, oncology marketing strategy, commercial sales, market access and government affairs.  She is experienced at leading cross-functional launch planning for cell therapy and other specialized hematology/oncology therapies. Ms. Korfin is the Chief Operating Officer and Chief Commercial Officer for Gamida Cell.  Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.  Ms. Korfin is responsible for leading the strategy and execution for operations for the omidubicel BLA and for the commercialization plans, post-FDA approval.  She also provides oversight for the operations and commercial strategy for the Natural Killer Cell platform. Prior to joining Gamida Cell, Ms. Korfin was the Chief Operating Officer of TYME Technologies.  Ms. Korfin’s focus at TYME was to advance the pivotal clinical trials for SM-88, an oral therapy and the lead investigational agent for the TYME proprietary cancer metabolism-based therapeutics (CMBTsTM) platform. Prior to joining TYME, Ms. Korfin was Vice President of Market Access at Kite Pharma, where she oversaw the market access strategy, including payer relations, reimbursement and government affairs for Yescarta®, the first approved CAR-T therapy in lymphoma. Ms. Korfin also established the Chain of Identity approach for the Kite CAR-T therapy and led the Kite Konnect team. Prior to joining Kite, Ms. Korfin spent more than a decade at Celgene in a variety of key strategic and operational roles, including Global Marketing, head of the U.S. oncology sales force, U.S. Market Access lead, Lymphoma Marketing lead, and overseeing the global development programs for REVLIMID® in Lymphoma and CLL. Ms. Korfin has also held prior positions at Merck & Co as a manufacturing scientist, Bain & Company as a consultant and Schering-Plough in sales and marketing. Ms. Korfin sits on the board of Organogenesis, a publicly traded biotech company with a focus on therapies for advanced wound care treatment and sports medicine.  She is also a board member for BioNJ and currently serves on the executive committee as Board Secretary. Ms. Korfin holds a Master in Business Administration from Harvard Business School and a Bachelor of Science degree in Pharmacy from Rutgers University.  Ms. Korfin is a licensed pharmacist in New Jersey.  She resides in New Jersey with her husband, Andy, and their two children, Amanda and Jake. Board Members

Source: BioNJ on 01/18/2023

 

By accessing ExecAtlas, you can view bios, network, connections and references of industry leading executives like Michele Ilene Korfin. More specifically, you'll be able to:

  • IDENTIFY executive and board member connections in Michele Ilene Korfin's network.
  • FOLLOW changes in Michele Ilene Korfin's employment.
  • CONNECT with Michele Ilene Korfin through your network of contacts.
 

Access over 1,500,000 executive and board member profiles.

Example: Michele Ilene Korfin

Michele Ilene Korfin's Connections (98)


Denise Machado
Executive Director, Member Operations, BioNJ
Vladimir Melnikov
Senior Vice President, Global Operations and Manufacturing, Gamida Cell Ltd.
Carrie Brown
Board Member, BioNJ
Investor Advisor
Board Member, BioNJ
Leigh Anne Leas
Former Board Member, BioNJ
Christian Kopfli Esq.
Former Board Member, BioNJ
George F. Heinrich
Board Member, KayoThera, Inc.
Robert I. Blum
President and Chief Executive Officer, Cytokinetics, Incorporated
Tzvi Palash
Chief Operating Officer, MediWound Ltd.
Michael S. Perry Ph.D.
Lead Director, Arrowhead Pharmaceuticals, Inc.